Olfactory testing represents an increasingly recognized component of the diagnostic assessment for corticobasal syndrome (CBS). While olfactory dysfunction has been extensively studied in Parkinson's disease (PD) and progressive supranuclear palsy (PSP), the profile in CBS has emerged as distinct and diagnostically informative. The pattern of olfactory impairment in CBS differs from both PD and PSP, reflecting the underlying pathological heterogeneity of the syndrome and providing a non-invasive window into disease-specific neurodegeneration.
CBS arises from multiple underlying pathologies, including corticobasal degeneration (CBD), PSP, Alzheimer's disease (AD), and TDP-43 proteinopathies. Each of these pathologies demonstrates different patterns of olfactory involvement, making olfactory testing potentially useful not only for diagnosis but also for predicting underlying pathology.
Olfactory dysfunction in CBS shows considerable variability depending on the underlying pathology:
| Measure | CBS (CBD pathology) | CBS (PSP pathology) | CBS (AD pathology) | CBS (TDP-43) |
|---------|---------------------|---------------------|---------------------|---------------|
| Olfactory dysfunction prevalence | 40-60% | 50-70% | 70-85% | 30-50% |
| Severe impairment (anosmia) | 10-20% | 15-25% | 30-40% | 5-15% |
| Mild-moderate impairment | 30-40% | 35-45% | 40-45% | 25-35% |
| Early-stage detection rate | 20-30% | 30-40% | 50-60% | 15-25% |
The wide range reflects the heterogeneous nature of CBS and the importance of pathological correlation[^kane2022].
The olfactory profile in CBS exhibits several distinctive features:
The UPSIT is a 40-item scratch-and-sniff test that provides comprehensive smell identification assessment:
| UPSIT Score | Interpretation | CBS Pathology Implication |
|-------------|---------------|--------------------------|
| ≥35 | Normosmia | Less likely AD pathology |
| 30-34 | Mild dysfunction | Compatible with CBD or TDP-43 |
| 25-29 | Moderate dysfunction | Compatible with PSP pathology |
| <25 | Severe dysfunction | Suggests AD co-pathology |
The UPSIT has been validated in CBS populations and demonstrates good test-retest reliability[^baba2012].
The Sniffin' Sticks test provides a comprehensive assessment of olfactory function across three domains:
The combined Threshold-Discrimination-Identification (TDI) score provides a comprehensive measure:
| TDI Score | Interpretation | CBS Context |
|-----------|---------------|-------------|
| >30 | Normosmia | Typical for early CBS |
| 25-30 | Mild dysfunction | Common at diagnosis |
| 16-25 | Moderate dysfunction | Suggests progression |
| <16 | Severe dysfunction | Consider AD co-pathology |
The Sniffin' Sticks test has been validated in European CBS cohorts and provides complementary information to UPSIT[^witjes2021].
The olfactory dysfunction in CBS stems from pathology affecting multiple components of the olfactory system:
The pattern of olfactory dysfunction correlates with underlying pathology:
Olfactory function correlates with disease progression in CBS:
| Feature | CBS | Parkinson's Disease |
|---------|-----|-------------------|
| Prevalence | 40-60% | 90-95% |
| Severity | Mild-moderate | Severe |
| Early detection | 20-30% | 70-80% |
| Progression | Slow | Moderate |
| Pattern | Variable | Identification deficit |
The key distinction is that PD almost universally shows severe olfactory impairment, while CBS shows variable dysfunction[^postuma2014].
| Feature | CBS | PSP |
|---------|-----|-----|
| Prevalence | 40-60% | 50-70% |
| Severity | Mild-moderate | Moderate |
| Pattern | Variable | Consistent |
| Early detection | 20-30% | 30-40% |
| Asymmetry | More common | Less common |
CBS with PSP pathology shows similar patterns to isolated PSP, while CBS with CBD pathology demonstrates more variable involvement[suzuki2023].
| Feature | CBS | MSA |
|---------|-----|-----|
| Prevalence | 40-60% | 20-30% |
| Severity | Mild-moderate | Typically mild |
| Pattern | Variable | Usually preserved |
Preserved olfaction strongly favors MSA over CBS in the differential diagnosis.
Olfactory testing assists in differentiating CBS from other parkinsonian syndromes:
| Condition | Typical Olfactory Function | Diagnostic Utility |
|-----------|---------------------------|-------------------|
| Parkinson's disease | Severely impaired | High (rule out CBS) |
| PSP | Moderately impaired | Moderate |
| CBS | Variable | Moderate |
| MSA | Typically preserved | High (rule in CBS) |
| CBD | Variable | Low-moderate |
Olfactory patterns may predict underlying pathology in CBS:
| Olfactory Profile | Predicted Pathology | Confidence |
|------------------|---------------------|-------------|
| Severe impairment | AD co-pathology | High |
| Moderate impairment | PSP pathology | Moderate |
| Mild dysfunction | CBD pathology | Low-moderate |
| Normal olfaction | TDP-43 pathology | Low |
Step 1: Initial Olfactory Assessment
Step 2: Pattern Analysis
| Pattern | Likely Underlying Pathology | Further Testing |
|---------|----------------------------|-----------------|
| Severe impairment (TDI < 16) | AD co-pathology | Amyloid PET, CSF biomarkers |
| Moderate impairment (TDI 16-25) | PSP pathology | Tau PET, clinical correlation |
| Mild impairment (TDI 25-30) | CBD pathology | MAPT genotyping |
| Normal olfaction (TDI > 30) | TDP-43 pathology | CSF TDP-43 |
Step 3: Integration with Clinical Features
Combine olfactory findings with:
Olfactory testing offers several practical advantages:
Olfactory measures correlate with clinical decline in CBS:
Olfactory testing may serve as:
Olfactory measures function as part of a comprehensive biomarker panel:
| Biomarker Category | CBS Signature | Clinical Utility |
|-------------------|--------------|------------------|
| Olfactory | Variable dysfunction | Moderate |
| Neuroimaging | Asymmetric cortical atrophy | High |
| CSF biomarkers | Elevated 4R-tau (if PSP pathology) | Moderate |
| Genetic | MAPT, GRN, APOE | Moderate |
Ongoing research examines: